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Abstract Our purpose was to characterize the risks of
osteoporosis-related subtrochanteric fractures in bis-
phosphonate-naive individuals. Baseline characteristics of
patients enrolled in the HORIZON-Recurrent Fracture
Trial with a study-qualifying hip fracture were examined,
comparing those who sustained incident subtrochanteric
fractures with those sustaining other hip fractures. Sub-
jects were bisphosphonate-naive or had a bisphosphonate
washout period of 6–24 months and subsequently received
an annual infusion of zoledronic acid 5 mg or placebo after
low-trauma hip-fracture repair. In total, 2,127 men and
women were included. Of the qualifying hip fractures,
5.2% were subtrochanteric, 54.8% femoral neck, 33.0%
intertrochanteric, and 7.1% other (generally complex
fractures of mixed type). Signiﬁcant baseline (pre-hip
fracture) differences were seen between index hip-fracture
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DOI 10.1007/s00223-011-9543-8types, with the percentage of patients with extreme
mobility problems being twofold higher in patients with
index subtrochanteric fracture (9.9%) compared to other
patients. The distribution of hip-fracture types was sim-
ilar between the treatment groups at baseline. No patients
with index subtrochanteric fractures and six patients with
other qualifying hip fractures reported prior bisphospho-
nate use. Only one further subtrochanteric fracture
occurred in each treatment group over an average 2-year
patient follow-up. Subtrochanteric fractures are not
uncommon in bisphosphonate-naive patients. Extreme
difﬁculties with mobility may be a unique risk factor
predisposing to development of incident subtrochanteric
fractures rather than other types of hip fracture. In
patients with recent hip fracture who received zoledronic
acid therapy, the incidence of new subtrochanteric
fractures was too small to draw any meaningful
conclusions.
Keywords Bisphosphonate  Hip fracture  Osteoporosis 
Subtrochanteric  Zoledronic acid
Recent publications have questioned the safety of bis-
phosphonates in the treatment of osteoporosis [1–6]. In
particular, concern has been raised regarding the devel-
opment of atypical subtrochanteric fractures in alendro-
nate-treated individuals potentially related to marked
suppression of bone turnover [2–4]. Atypical fractures are
fractures that occur in diaphyseal and subtrochanteric sites
after minimal trauma, such as a fall from standing height
or lower. Thickened cortices differentiate these atypical
fractures from the thin cortices seen with typical osteo-
porotic fractures. Subtrochanteric fractures, however, are
known to occur in patients suffering from osteoporosis
who have never been treated with bisphosphonates. The
question then arises whether incident subtrochanteric
fractures in bisphosphonate-treated individuals are a
consequence of the underlying condition or due to ther-
apy. Little is known about the epidemiology of these
osteoporosis-related subtrochanteric fractures in older
adults, and such information may be helpful in untangling
emerging data about atypical, bisphosphonate-related
subtrochanteric fractures.
Patients with a low-trauma hip fracture have one of the
highest risks of subsequent fracture, including a high risk
of hip-fracture recurrence [7, 8]. In order to better under-
stand the epidemiology and outcomes of subtrochanteric
fractures in osteoporotic patients who were bisphospho-
nate-naive, we examined the baseline characteristics from
the HORIZON-Recurrent Fracture Trial (RFT) to deter-
mine the risks for incident osteoporosis-related subtro-
chanteric fractures.
Methods
Design Overview
This was a post-hoc analysis of the HORIZON-RFT, a
randomized, placebo-controlled, double-blind study, which
recruited subjects aged C50 years who had undergone
surgical repair of a low-trauma hip fracture in the preced-
ing 90 days [5].
Setting and Participants
The HORIZON-RFT evaluated the safety and efﬁcacy of a
once-yearly bisphosphonate, zoledronic acid, in preventing
new clinical fractures in a total of 2,127 patients with recent
low-trauma hip-fracture repair. Patients were unwilling or
unable to take an oral bisphosphonate. Prior use of bis-
phosphonates or parathyroid hormone was allowed, with a
washout period determined by the drug and the duration of
its use. The washout periods for any oral bisphosphonate
were 2 years (if used for more than 48 weeks), 1 year (if
used for 8–48 weeks), and 6 months (if used for
2–8 weeks). This post-hoc analysis focused on subjects
with subtrochanteric hip fractures as their qualifying
(index) hip fracture for entry into the study, prior to any
study drug administration. Index fracture site (subtrochan-
teric, femoral neck/subcapital, intertrochanteric, or other)
was recorded by the investigator at the time of enrollment,
but index hip-fracture radiographs were not collected.
Informed consent was obtained from subjects, and
investigations were approved by an institutional human
research committee. The study was conducted according to
the ethical principles of the 1989 Declaration of Helsinki
and local applicable laws and regulations.
Randomization and Interventions
Patients were assigned at random to receive an intravenous
infusion of zoledronic acid 5 mg (Novartis Pharma, Basel,
Switzerland) (n = 1,065) or placebo (n = 1,062) once
yearly. Both groups received a loading dose of vitamin D2
or D3 intramuscularly or orally, followed by 800–1,200 IU
vitamin D and 1,000–1,500 mg elemental calcium orally
on a daily basis. Concomitant antiresorptive therapy with
calcitonin, hormone-replacement therapy, selective estro-
gen receptor modulators, and tibolone was allowed. All
study procedures were approved by the local institutional
review board at each participating site.
Outcomes and Follow-Up
Subsequent clinically apparent fractures, including second
hip fractures, were the primary end point and were
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123adjudicated by a blinded central committee that reviewed
radiographs and radiograph reports.
Potential risk factors for index hip subtrochanteric
fracture were determined for each subject. Baseline
comorbidities, demographics, and prior osteoporosis ther-
apy were recorded at baseline. Bone mineral density
(BMD) was measured at baseline and yearly thereafter.
Other measures that were used in the present analysis
include EQ-5D total score and each of the separate
dimensions, additional fractures after randomization, and
survival status. Laboratory values were measured at a
central laboratory prior to study drug infusion.
Statistical Analysis
A univariate logistic regression model was used to test if a
predictor variable was associated with the index hip sub-
trochanteric fracture. The model was also used to deter-
mine whether place of residence following the index
hospitalization was affected by the type of index hip
fracture. A Cox regression model stratiﬁed by treatment
group was used to evaluate whether the incidence rates of
subsequent clinical fracture, hip fracture, and death during
the study were higher in patients with index hip subtro-
chanteric fracture compared to other patients. Analysis of
covariance models were used to evaluate the between-
index hip-fracture type difference in change from baseline
EQ-5D visual analogue scale (VAS) and utility scores
during the study.
Results
Of the qualifying hip fractures, 5.2% were subtrochanteric,
54.8% femoral neck, 33.0% intertrochanteric, 7.1% other
(generally complex fractures of mixed type), and 0.1%
missing. Of the 106 subjects in the study who had sustained
a baseline qualifying subtrochanteric fracture, 50 were
randomly assigned to zoledronic acid 5 mg therapy and 56
to placebo (Table 1).
In examining the baseline characteristics for those with
subtrochanteric fractures relative to those who had sus-
tained other types of hip fractures, no signiﬁcant differ-
ences were observed between groups in the majority of
factors (Table 2). The percentage of patients with extreme
mobility problems (conﬁned to bed) was twofold higher in
patients with index subtrochanteric fracture (9.9%) com-
pared with other patients (4.7%). In all, a signiﬁcantly
higher proportion of patients with subtrochanteric fractures
at baseline had problems walking (i.e., mobility problems)
than did patients with other hip fractures at baseline (82.2
vs. 77.1%, respectively; logistic regression P = 0.05)
(Table 2). In total, 4.7% of subjects with subtrochanteric
fractures and 5.1% with other hip-fracture types reported
taking permitted concomitant osteoporosis treatment at the
time of their index fracture (Table 3). However, no patients
with index subtrochanteric fractures and only six patients
with other types of qualifying hip fractures reported any
prior use of bisphosphonates.
There was no difference in the incidence of death in
patients with index subtrochanteric relative to other hip
fractures. There was a trend for reduced risk of subsequent
fracture over 24 months in those with index subtrochan-
teric fractures compared with other types of index hip
fractures (3.47 vs. 11.61%, hazard ratio [HR] = 0.43, 95%
conﬁdence interval [CI] 0.18–1.03; P = 0.05). Patients
with index subtrochanteric fractures were also numerically
less likely to have a subsequent hip fracture (HR = 0.75,
95% CI 0.18–3.07; P = 0.68) over 24 months than those
with other index hip fractures, although the difference was
not statistically signiﬁcant. At the end of the study, the
mean increases in EQ-5D VAS scores and utility scores
were signiﬁcantly larger in patients with index subtro-
chanteric fractures compared to patients with other index
hip-fracture types (P = 0.04 and P = 0.001, respectively)
(Fig. 1). There was no difference between index hip-frac-
ture types in the proportion of patients with extreme
problems in the EQ-5D proﬁle at the end of the study. The
only exception was in patients with other types of index hip
fracture, who were signiﬁcantly more likely to have
extreme problems with self-care than those with an index
subtrochanteric fracture (at baseline, the difference was not
statistically signiﬁcant) (Fig. 2). Patients with index sub-
trochanteric fractures were numerically less likely than
those with other index hip fractures to be discharged to an
assisted living facility or nursing home following the index
hospitalization (odds ratio 0.90, 95% CI 0.52–1.56), but
this difference was not statistically signiﬁcant (P = 0.70).
In the overall study population, the rate of new hip frac-
tures was 2.0% (23/1,065) in the zoledronic acid group and
3.5% (33/1,062) in the placebo group (P = 0.18). There
were two subsequent subtrochanteric fractures reported as
adverse events: one in the zoledronic acid group and one in
Table 1 Location of qualifying hip fracture
Location of qualifying
hip fracture
Zoledronic acid
(n = 1,065), n (%)
Placebo
(n = 1,062), n (%)
Intertrochanteric 358 (33.6) 344 (32.4)
Subtrochanteric 50 (4.7) 56 (5.3)
Subcapital 220 (20.7) 213 (20.1)
Femoral neck 357 (33.5) 374 (35.2)
Other 78 (7.3) 75 (7.1)
Missing 2 (0.2) 0 (0.0)
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123Table 2 Baseline (pre-hip
fracture) characteristics (ITT
population)
BMI Body mass index, SD
standard deviation, ITT intention
to treat
a Based on a univariate logistic
regression model to test if a factor
was associated with the index hip
subtrochanteric fracture
b Assisted living, skilled nursing
facility, rehabilitation center,
acute care hospital, other, missing
c Dementia, dementia Alzheimer-
type, senile dementia, or vascular
dementia
Subtrochanteric hip fracture
(n = 106)
Other hip fracture
(n = 2,021)
P
a
Age (years)
Mean (SD) 73.9 (9.26) 74.5 (9.69) 0.51
Group, n (%) 0.51
\65 21 (19.8) 343 (17.0)
65–74 27 (25.5) 549 (27.2)
75–84 48 (45.3) 847 (41.9)
C85 10 (9.4) 282 (14.0)
Sex, n (%) 0.27
Male 30 (28.3) 478 (23.7)
Female 76 (71.7) 1543 (76.3)
BMI, mean (SD) 24.6 (4.20) 24.8 (4.44) 0.74
Bone mineral density, (g/cm
2)
Femoral neck, mean (SD) 0.654 (0.1235) 0.649 (0.1245) 0.74
Total hip, mean (SD) 0.709 (0.1846) 0.697 (0.1509) 0.47
T score at femoral neck, n (%) 0.71
B-2.5 48 (45.3) 840 (41.6)
[-2.5 to B-1.5 39 (36.8) 696 (34.4)
[-1.5 10 (9.4) 234 (11.6)
Missing 9 (8.5) 251 (12.4)
Prior bisphosphonate use, n (%) 0 (0.0) 6 (0.3) 0.99
Concomitant osteoporosis therapy, n (%) 5 (4.7) 103 (5.1) 0.86
Other current medications, n (%)
Corticosteroids 2 (1.9) 63 (3.1) 0.48
Anticonvulsants 4 (3.8) 62 (3.1) 0.68
Psychoactive medications 0 2 (0.1) 0.99
Creatinine clearance (mL/min), mean
(SD)
74.8 (26.73) 70.0 (26.72) 0.08
EQ-5D
Mean total score (SD) 0.55 (0.311) 0.57 (0.297) 0.41
Mobility, n (%) 0.05
With problem/extreme problem 83 (82.2) 1,497 (77.1)
With extreme problem 10 (9.9) 91 (4.7)
Self-care, n (%) 0.94
With problem/extreme problem 54 (54.0) 1,049 (54.1)
With extreme problem 6 (6.0) 134 (6.9)
Activities, n (%) 0.97
With problem/extreme problem 71 (71.7) 1398 (72.6)
With extreme problem 19 (19.2) 387 (20.1)
Pain, n (%) 0.25
With problem/extreme problem 60 (59.4) 1242 (64.1)
With extreme problem 5 (5.0) 55 (2.8)
Anxiety/depression, n (%) 0.66
With problem/extreme problem 39 (39.4) 755 (39.0)
With extreme problem 2 (2.0) 72 (3.7)
Thermometer (VAS), mean (SD) 67.7 (16.75) 65.7 (17.97) 0.26
Place of residence prior to qualifying hip
fracture
0.99
Private residence 94 (88.68) 1,790 (88.57)
Other
b 12 (11.32) 231 (11.43)
History of active dementia
c 2 (1.89) 133 (6.58) 0.07
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123the placebo group. Neither was reported as an atypical
fracture with thickened cortices. As a result, no conclusions
could be drawn about subtrochanteric fractures in the
24 months post-zoledronic acid therapy in this group of
patients with a hip fracture at baseline. Further, in the safety
analysis of the overall study population, no adverse effects
on the healing of fractures were noted. Speciﬁcally, blinded
adjudication by a panel of external experts found that there
were no differences between treatment groups in delayed
fracture healing or nonunion, regardless of fracture type or
time of study drug infusion.
Discussion
The long-term safety of bisphosphonates for the treatment
of osteoporosis has been questioned. Several case series
have suggested a link between prolonged bisphosphonate
therapy and atypical fractures [1–5]. In an early report,
three patients sustained low-energy nonvertebral fractures
of the femoral shaft while receiving long-term alendronate
therapy, with bone biopsies showing evidence of severely
suppressed bone turnover and fracture healing that was
either delayed or absent [1]. Low-energy subtrochanteric
fractures were associated with prodromal pain in the
affected hip in the months preceding the fall, with a stress
reaction demonstrated in the cortex in the contralateral
femur [4] and a simple, transverse fracture with a unicor-
tical beak in an area of cortical hypertrophy often seen
associated with alendronate use [2]. A unique radiographic
pattern, deﬁned as a simple transverse or oblique (B30)
fracture with beaking of the cortex and diffuse cortical
thickening of the proximal femoral shaft, has been reported
with cortical thickening present in the contralateral femur
in all patients with this pattern [3].
In a more recent study examining atypical fractures of
the subtrochanteric or diaphyseal femur, it was reported
that these fractures were rare and that in this (albeit
underpowered) study, no signiﬁcant increase in risk was
seen in association with bisphosphonate use for as long as
10 years [6]. In addition, the results from a register-based
national cohort study and cross-sectional analysis con-
ducted in Denmark did not support previous suggestions of
increased risk of atypical subtrochanteric fractures as a
consequence of long-term bisphosphonate use [9].
Little is known about the epidemiology of typical,
osteoporosis-related subtrochanteric fractures in older
adults. A better understanding of the risk factors, incidence,
and outcomes of these fractures is useful to frame the
debate about atypical, bisphosphonate-related subtrochan-
teric fractures. Prior studies have suggested that subtro-
chanteric fractures make up approximately 5–10% of hip
fractures in older adults [10]. The incidence appears to be
higher in Asians than in other populations, and this has
been hypothesized to relate to higher prevalence of osteo-
malacia [11]. It is not clear whether risk factors or out-
comes of these fractures differ from other types of hip
fracture.
The HORIZON-RFT, as a large-scale, randomized,
controlled trial in a high-risk population who had already
sustained a hip fracture and including a subset of patients
with an index subtrochanteric fracture, provided a unique
framework for meaningful data on bisphosphonate use and
osteoporosis-related subtrochanteric fracture risk. Data
were systematically collected at the time of study entry,
and it was observed that 5.2% of patients had sustained an
index subtrochanteric fracture; all were bisphosphonate-
naive. Unfortunately, we were not able to determine
whether these patients exhibited the thickened cortices
associated with atypical subtrochanteric fractures. Subjects
with an index subtrochanteric fracture were signiﬁcantly
more likely to report baseline mobility problems than
those with other types of index hip fractures and were
likely to have signiﬁcantly greater increases in EQ-5D
VAS and utility scores (i.e., greater declines in condition).
Table 3 Concomitant osteoporosis therapy at the time of index
fracture (ITT population)
Therapy preferred term Subtrochanteric hip
fracture (n = 106),
n (%)
Other hip fracture
(n = 2,021),
n (%)
Total 5 (4.7) 103 (5.1)
Estrogens, conjugated 0 (0.0) 24 (1.2)
Calcitonin, salmon 0 (0.0) 21 (1.0)
Estradiol, estriol,
estrogens
3 (2.8) 29 (1.4)
SERM (raloxifene
hydrochloride,
tamoxifen citrate)
1 (0.9) 17 (0.84)
Calcitonin 0 (0.0) 4 (0.2)
Tamoxifen 0 (0.0) 3 (0.1)
Alendronate sodium 0 (0.0) 2 (0.1)
Tibolone 0 (0.0) 2 (0.1)
Risedronate sodium 0 (0.0) 2 (0.1)
Etidronate disodium 0 (0.0) 2 (0.1)
Medroxyprogesterone
acetate
0 (0.0) 1 (0.05)
Raloxifene 0 (0.0) 1 (0.05)
Fluoride 1 (0.9) 0 (0.0)
A patient with multiple occurrences of the same medication under one
treatment is counted only once in that preferred term for that treat-
ment. Preferred terms are sorted in descending frequency, as reported
in the other hip-fracture group
SERM Selective estrogen receptor modulator, ITT intention to treat
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123These ﬁndings suggest that subtrochanteric fractures might
be associated with greater postoperative mobility limita-
tions and poorer health outcomes overall than other hip-
fracture types. Although the results suggest that mobility
problems might be a risk factor for subtrochanteric frac-
tures, some inconsistencies in the data, for example, that
patients with other types of hip fracture were signiﬁcantly
more likely to have extreme problems with self-care at the
end of the study, suggest that this could be a chance ﬁnd-
ing, particularly since only univariate analysis was
performed.
Over the course of the study, only two subtrochanteric
fractures occurred; and once again, we could not determine
whether these were atypical subtrochanteric fractures with
thickened cortices. However, our study adds to the under-
standing of subtrochanteric fractures as a type of osteo-
porotic hip fracture with similar risk factors and outcomes
to intertrochanteric and femoral neck fractures. Additional
studies are needed to accurately distinguish ‘‘atypical’’
fractures possibly associated with bisphosphonate use from
the more common subtrochanteric fracture related to
osteoporosis.
Our study is not without limitations. Our greatest limi-
tation was that the subtrochanteric fractures were ‘‘repor-
ted,’’ without knowledge of time of occurrence, and not
reviewed by a radiologist to conﬁrm that they were indeed
subtrochanteric fractures, a similar limitation identiﬁed in
the post-hoc analysis recently published by Black and
colleagues using data from the HORIZON-RFT, FIT and
FLEX trials [6]. Unfortunately, both the baseline and fol-
low-up X-rays are not readily available for review. As a
result, the fractures could not be fully characterized. In
addition, there was no central reading of the index hip
fractures. However, despite some limitations, this analysis
Fig. 1 Between-hip-fracture type comparison of change from base-
line in a EQ-5D Visual Analogue Scale (VAS) and b EQ-5D utility
scores by visit (intention-to-treat population). a *P = 0.02,
**P = 0.04. b *P = 0.006, **P = 0.025, ***P = 0.001. n number
of patients with measurements at both baseline and postbaseline
visits, CI conﬁdence interval. Scale 0 corresponds to worst possible
health and 100 corresponds to perfect health. Error bars show
standard error of least squares mean (LSM). Value at end of study
visit is hip-fracture type difference, i.e., the LSM difference of
subtrochanteric hip fracture versus other hip fracture on the change
from baseline. The P value is obtained from an analysis of covariance
model, with baseline score, region, treatment, and hip-fracture type as
explanatory variables
Fig. 2 Proportion of patients
with extreme problem in EQ-5D
proﬁle by dimension at end of
study (intention-to-treat
population). *P = 0.009.
n number of patients with
measurement for visit. P value
obtained from Fisher’s exact
test
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123provides important additional information on the incidence
and risk of subtrochanteric fractures.
Conclusions
Our post-hoc analysis demonstrated that osteoporosis-
related subtrochanteric fractures are not uncommon and do
occur in bisphosphonate-naive patients. In patients with
recent hip fracture, extreme problems with mobility may
have been a predisposing risk factor to the development of
incident subtrochanteric fractures. Finally, the incidence of
subtrochanteric fractures post-zoledronic acid therapy was
rare and too small to draw any meaningful conclusions
about the occurrence of new subtrochanteric fractures with
short-term zoledronic acid therapy.
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